Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under load

2015/06/24 by Anastasia Karabina, Katarzyna Kazmierczak, Katarzyna Kaźmierczak +3 · 23 citations
Biochemistry, Genetics and Molecular Biology · Chemistry · Medicine · #Actin #Biochemistry #Biology #Biophysics #Cardiomyopathy and Myosin Studies #Cardiovascular Effects of Exercise #Cell biology #Chemistry #Gene #MYH7 #Muscle Physiology and Disorders #Mutant #Myosin #Myosin light-chain kinase #Phosphorylation

paper · doi:10.1016/j.abb.2015.06.014

openalex publication_date 2015/06/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Cited by

• N-Terminus of Cardiac Myosin Essential Light Chain Modulates Myosin Step-Size. [europepmc]
• Various Themes of Myosin Regulation. [europepmc]
• Gene expression patterns in transgenic mouse models of hypertrophic cardiomyopathy caused by mutations in myosin regulatory light chain. [europepmc]
• A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation. [europepmc]
• Molecular and Functional Effects of a Splice Site Mutation in the MYL2 Gene Associated with Cardioskeletal Myopathy and Early Cardiac Death in Infants. [europepmc]
• Transmural gradients of myocardial structure and mechanics: Implications for fiber stress and strain in pressure overload. [europepmc]
• Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin. [europepmc]
• Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice. [europepmc]
• Slow-twitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chain. [europepmc]
• Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain. [europepmc]
• Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains. [europepmc]
• Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies. [europepmc]
• Mavacamten decreases maximal force and Ca 2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. [europepmc]
• Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics. [europepmc]
• Impact of regulatory light chain mutation K104E on the ATPase and motor properties of cardiac myosin. [europepmc]
• Shared Molecular Mechanisms of Hypertrophic Cardiomyopathy and Its Clinical Presentations: Automated Molecular Mechanisms Extraction Approach. [europepmc]
• Functional and Molecular Characterisation of Heart Failure Progression in Mice and the Role of Myosin Regulatory Light Chains in the Recovery of Cardiac Muscle Function. [europepmc]
• Bridging the muscle genome to phenome across multiple biological scales. [europepmc]
• Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function. [europepmc]
• Functional comparison of phosphomimetic S15D and T160D mutants of myosin regulatory light chain exchanged in cardiac muscle preparations of HCM and WT mice. [europepmc]
• Peculiarities of the Acetylcholine Action on the Contractile Function of Cardiomyocytes from the Left and Right Atria in Rats. [europepmc]
• Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin. [europepmc]
• Modeling the effects of thin filament near-neighbor cooperative interactions in mammalian myocardium. [europepmc]